LungÕ 2026 – Virtual Global Congress on Lung Oncology
ASTRIDE Bridges the Gap: Serplulimab Matches 32% Two-Year Survival in U.S. Patients with Small Cell Lung Cancer
Daniel Malarek and a Wish for Oncology: A Future Where Breakthroughs Reach Every Patient
Perioperative Ivonescimab Shows Promising Pathological Responses in Resectable NSCLC: Phase II Trial Reports 70.1% MPR and 50.7% pCR
Expert Discussion at COGC 2026: The Right First Investments in Precision Oncology
From TAILORx to OPTIMA: Genomic Testing Expands Chemotherapy De-escalation in Higher-Risk HR-Positive Breast Cancer
BeOne Medicines’ Zanubrutinib Combination Gains FDA Priority Review for First-Line Mantle Cell Lymphoma
London Global Cancer Week 2026: Highlights From November 2–4
OncoDaily GI is the dedicated GI cancer platform of OncoDaily, focused on the rapidly evolving field of gastrointestinal oncology. It covers the full spectrum of GI malignancies, including colorectal, anal canal, gastric, gastroesophageal junction (GEJ), esophageal, small bowel, pancreatic, hepatocellular, and biliary tract cancers. Through OncoDaily GI, readers can follow the latest clinical trial developments, ongoing research, FDA and EMA approvals, guideline updates, emerging therapies, advances in biomarkers and precision oncology, major conference findings, and interviews with leading experts in the field.
